Novel Kv1.3 blockers for immunosuppression: WO2012155199

Bibliography

• Nguyen W, Howard BL, Neale DS, et al. Use of Kv1.3 blockers for inflammatory skin conditions. Curr Med Chem 2010;17:2882-96
   Google Scholar
• Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-7
   PubMed Web of Science ®Google Scholar
• Global Autoimmune Disease Therapeutics Market to Exceed US$77 Billion by 2017, According to New Report by Global Industry Analysts, Inc. PRWeb. 2011. Available from: www.prweb.com/releases/autoimmune_disease/therapeutics_drugs/prweb8957282.htm [Last accessed 1 June 2013]
   Google Scholar
• Chandy KG, Wulff H, Beeton C, et al. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004;25:280-9
   PubMed Web of Science ®Google Scholar
• Cahalan MD, Wulff H, Chandy KG. Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 2001;21:235-52
   PubMed Web of Science ®Google Scholar
• Lin CS, Boltz RC, Blake JT, et al. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J Exp Med 1993;177(3):637-45
   Google Scholar
• DeCoursey TE, Chandy KG, Gupta S, et al. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature 1984;307:465-8
   PubMed Web of Science ®Google Scholar
• Wulff H, Calabresi PA, Allie R, et al. The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J Clin Invest 2003;112:298-8
   Google Scholar
• Wulff H, Knaus H-G, Pennington M, et al. K+ Channel Expression during B Cell Differentiation: Implications for Immunomodulation and Autoimmunity. J Immunol 2004;173:776-86
   PubMed Web of Science ®Google Scholar
• Chandy KG, Wulff H, Beeton C, et al. Kv1.3 potassium channel: physiology, pharmacology and therapeutic indications. In: Mannhold R, Kubinyi H, Folkers G, et al. Voltage-gated ion channels as drug targets. Wiley-VCH Verlag GmbH & Co, Weinheim, Germany; 2006. p. 214-74
   Google Scholar
• Kalman K, Pennington MW, Lanigan MD, et al. ShK-Dap22, a potent Kv1.3-specific Immunosuppressive Polypeptide. J Biol Chem 1998;273:32697-707
   PubMed Web of Science ®Google Scholar
• Beeton C, Wulff H, Barbaria J, et al. Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001;98:13942-7
   PubMed Web of Science ®Google Scholar
• Gocke AR, Lebson LA, Grishkan IV, et al. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J Immunol 2012;188:5877-86
   Google Scholar
• Baell JB, Gable RW, Harvey AJ, et al. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem 2004;47:2326-36
   PubMed Web of Science ®Google Scholar
• Harvey AJ, Baell JB, Toovey N, et al. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J Med Chem 2006;49:1433-41
   PubMedGoogle Scholar
• MS drug development agreement based on WEHI's medicinal chemistry. Walter and Eliza Hall Institute of Medicinal Research. 2008. Available from: http://www.wehi.edu.au/site/latest_news/ms_drug_development_agreement_based_on_wehis_medicinal_chemistry [Last accessed 1 June 2013]
   Google Scholar
• Bionomics to Expand KV1.3 Program After Ending Agreement With Merck Serono FirstWorld Pharma. 2012. Available from: http://www.firstwordpharma.com/node/993223?tsid=17 [Last accessed 1 June 2013]
   Google Scholar
• Bionomics Ltd. Novel benzofuran potassium channel blockers and uses thereof. WO2008040057; 2008
   Google Scholar
• Bionomics Ltd. Novel chromenone potassium channel blockers and uses thereof. WO2008040058; 2008
   Google Scholar
• Bionomics Ltd. Novel aryl potassium channel blockers and uses thereof. WO2009043117; 2009
   Google Scholar
• Hanson DC, Nguyen A, Mather RJ, et al. UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br J Pharmacol 1999;126:1707-16
   PubMed Web of Science ®Google Scholar
• Burgess LE, Koch K, Cooper K, et al. The SAR of UK-78,282: a novel blocker of human T cell Kv1.3 potassium channels. Bioorg Med Chem Lett 1997;7:1047-52
   Google Scholar
• Tamargo J, Caballero R, Gómez R, et al. IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Invest Drugs 2009;18:399-416
   PubMed Web of Science ®Google Scholar
• Brendel J, Peukert S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Expert Opin Ther Patents 2002;12:1589-98
   Web of Science ®Google Scholar
• Koo GC, Blake JT, Shah K, et al. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol 1999;197:99-107
   PubMed Web of Science ®Google Scholar
• Haffner CD, Thomson SA, Guo Y, et al. Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett 2010;20:6989-92
   Google Scholar
• Xention Ltd. Compounds. US20110136860A1; 2010
   Google Scholar
• Xention Ltd. Novel potassium channel blockers. US20100087428; 2010
   Google Scholar
• Miao S, Bao J, Garcia ML, et al. Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett 2003;13:1161-4
   Google Scholar
• Vennekamp J, Wulff H, Beeton C, et al. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 2004;65:1364-74
   PubMed Web of Science ®Google Scholar
• Schmitz A, Sankaranarayanan A, Azam P, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 2005;68:1254-70
   PubMed Web of Science ®Google Scholar
• Azam P, Sankaranarayanan A, Homerick D, et al. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 2007;127:1419-29
   PubMed Web of Science ®Google Scholar
• Wulff H. Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840. Expert Opin Ther Patents 2010;20:1759-65
   PubMed Web of Science ®Google Scholar
• Nguyen W, Howard BL, Jenkins DP, et al. Structure–activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorg Med Chem Lett 2012;22:7106-9
   Google Scholar